IPOs in the medical device sector are bigger than in biotech, but performance, at least of the biggest groups, is mixed.
Spacs still have their supporters, but SEC scrutiny and mixed post-deal performance mean that the story is losing its lustre.
Private device makers enjoy the biggest quarter for four years – and the average deal is larger than ever.
Big risers include Eli Lilly, Biogen, Moderna and Biontech.
Emergence from lockdown is the driving force behind many – but not all – of the small and mid-cap share price moves.
Biopharma scores a $5bn quarter as another big year builds for venture financing.
Shareholders are rewarding the kinds of companies they punished a year ago.
IPOs of drug developers raised $9bn in the first half of 2021, a record amount that is hard to square with talk of moderation.
Acumen is the latest player to take aim at amyloid, but competition is fierce.